Some encouraging growth signals – Elan plans to ramp up after its recent brush with near-death, and Daiichi Sankyo plans a major U.S. sales force expansion.
Novartis takes the high road with genetic research into diabetes, sharing information openly. (Excerpt: Novartis, the Basel, Switzerland, drug giant, has helped uncover which of the 20,000 genes identified by the Human Genome Project are likely to be associated with diabetes. But rather than hoard this information, as drug firms have traditionally done, it is making it available for free on the World Wide Web…)
Another one of those early-on “teaser” news items: possible weakness detected in the AIDS virus.
Rutgers launches MBA program for pharma management.
J&J makes an interesting and controversial venture to the big screen – Innerstate, a 60-minute documentary about inflammatory diseases, without mentioning product during the entire production (J&J’s Centocor manufactures Remicade).
How small companies roll the dice and (sometimes!) win big with castoff drug candidates from Big Pharma.